Moreover, blocking of TPL2 activity through gene deletion or pharmacological inhibition was shown to inhibit tumor progression of hematopoietic malignancies and promote tumor shrinkage by suppressing the pro-inflammatory signature of TAMs and increasing the M1 (iNOS+)/M2 (Arg+) macrophage ratio in a tumor-stage dependent manner 68, 69. The gene discussed is MAP3K8; the disease is neoplasm.